Coherus Biosciences | CHRS - Sales Revenues


Coherus Biosciences reported $12.75M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
AbbVie USD 16.99B 1.99B Jun/2026
Acadia Pharmaceuticals USD 268.06M 15.94M Mar/2026
Akebia Therapeutics USD 57.62M 1.14M Dec/2025
ALKERMES USD 496.01M 103.1M Jun/2026
Alnylam Pharmaceuticals USD 1.29B 120M Jun/2026
Amarin USD 49.22M 451K Dec/2025
Amgen USD 8.62B 1.28B Mar/2026
Baxter International USD 2.96B 260M Jun/2026
Biogen USD 2.74B 490M Jun/2026
BioMarin Pharmaceutical USD 766M 109M Mar/2026
Bristol-Myers Squibb USD 12.97B 1.48B Jun/2026
Coherus Biosciences USD 12.75M 1.18M Dec/2025
Eli Lilly USD 19.8B 500M Mar/2026
Fujifilm JPY 927.25B 69.9B Mar/2026
Gilead Sciences USD 7B 930M Mar/2026
Ironwood Pharmaceuticals USD 106.51M 58.8M Mar/2026
Merck USD 16.29B 110M Mar/2026
Myriad Genetics USD 190.7M 9.7M Jun/2026
Pacira USD 177M 19.87M Mar/2026
Perrigo USD 969M 141M Mar/2026
Pfizer USD 14.5B 3.08B Mar/2026
PTC Therapeutics USD 361M 88M Jun/2026
Regeneron Pharmaceuticals USD 4.29B 690M Jun/2026
Sarepta Therapeutics USD 730.8M 287.9M Mar/2026
Teva Pharmaceutical Industries USD 12.67B 900M Jun/2026
Vertex Pharmaceuticals USD 2.99B 200M Mar/2026
Xencor USD 4.51M 23.73M Mar/2026
Zoetis USD 2.3B 100M Mar/2026